Aerovate Therapeutics, Inc.
AVTE
$2.68
-$0.04-1.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 73.40% | 17.00% | -30.22% | -40.35% | -35.89% |
| Total Depreciation and Amortization | -71.43% | 772.00% | 27.27% | 33.33% | 40.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.70% | -36.52% | 32.48% | 100.88% | 102.27% |
| Change in Net Operating Assets | -307.39% | -204.54% | -31.47% | -217.67% | 425.35% |
| Cash from Operations | 25.36% | -2.77% | -36.74% | -107.22% | 0.44% |
| Capital Expenditure | -- | -- | -- | -- | -1,500.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 129.85% | 222.67% | 348.54% | -42.61% | -60.58% |
| Cash from Investing | 132.45% | 222.37% | 351.92% | -42.55% | -61.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.65% | -76.84% | -46.19% | 215.70% | -21.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 53.46% | -- | 100.00% |
| Cash from Financing | 19.65% | 10.00% | -46.17% | 111.21% | 29.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.34% | 100.16% | -36.07% | -444.25% | -39,395.45% |